202 related articles for article (PubMed ID: 24884643)
41. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
[TBL] [Abstract][Full Text] [Related]
42. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).
Nakayama G; Uehara K; Ishigure K; Yokoyama H; Ishiyama A; Eguchi T; Tsuboi K; Ohashi N; Fujii T; Sugimoto H; Koike M; Fujiwara M; Ando Y; Kodera Y
Cancer Chemother Pharmacol; 2012 Oct; 70(4):575-81. PubMed ID: 22886005
[TBL] [Abstract][Full Text] [Related]
43. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metasta
